Comparative Pharmacology
Head-to-head clinical analysis: DEXLANSOPRAZOLE versus PREVACID NAPRAPAC 250 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXLANSOPRAZOLE versus PREVACID NAPRAPAC 250 COPACKAGED.
DEXLANSOPRAZOLE vs PREVACID NAPRAPAC 250 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell.
Lansoprazole: Proton pump inhibitor that irreversibly inhibits H+/K+ ATPase in gastric parietal cells, reducing gastric acid secretion. Naproxen: Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
30 mg orally once daily for 4 weeks for healing of erosive esophagitis; maintenance therapy: 30 mg orally once daily for up to 6 months. For GERD: 30 mg orally once daily for 4 weeks.
Lansoprazole 15 mg plus naproxen 250 mg orally twice daily.
None Documented
None Documented
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Technetium Tc-99m medronate
"The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderate1-2 hours; clinical context: duration of acid suppression exceeds half-life due to binding to proton pumps
Naproxen: 12-17 hours (terminal), allows twice-daily dosing. Lansoprazole: 1-2 hours (terminal), but acid suppression persists due to accumulation in parietal cells.
Renal: 0% unchanged; metabolites eliminated via urine (51%) and feces (48%)
Naproxen: Renal (95% as unchanged drug and metabolites, primarily 6-O-desmethyl naproxen), fecal (<5%). Lansoprazole: Renal (20% as metabolites), fecal (80% as metabolites).
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination
Dexlansoprazole + Pamidronic acid
"The therapeutic efficacy of Pamidronic acid can be decreased when used in combination with Dexlansoprazole."